Vitruvias Therapeutics Inc. has initiated a nationwide voluntary recall of one lot of its Thyroid Tablets, USP 30 mg, identified as Lot No. 504950, due to confirmed potential for super potency.
Consumption of these superpotent tablets can lead to hyperthyroidism, presenting symptoms such as weight loss, heat intolerance, fatigue, and cardiac issues like rapid heart rate. Elderly individuals, pregnant women, and infants face a higher risk of adverse outcomes, including maternal and fetal complications or negative effects on infant growth and development, especially with prolonged exposure.
Despite the potential risks, Vitruvias Therapeutics has not yet received any reports of adverse events directly linked to this specific recall.